quizartinib
daiichi sankyo
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'quizartinib', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)']
quizartinib more than doubled overall survival among patients newly diagnosed with flt3-itd-positive aml compared with standard chemotherapy, new phase 3 data show. #eha2022
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.